Dalia Rotstein



Research Programs


Dr. Dalia Rotstein is an attending staff neurologist at St. Michael’s Hospital, where she specializes in multiple sclerosis (MS). She is also an Assistant Professor in the Department of Medicine, Division of Neurology at the University of Toronto. Her research is focused on the epidemiology of MS, disease modifying therapy, and dietary and nutritional influences on MS. Recent work includes studies of incidence and prevalence patterns of MS in Ontario, interactions between vitamin D supplementation and disease modifying therapy, and the relationship between BMI and MS disease course. Dr. Rotstein is also investigating No Evidence of Disease Activity (NEDA), a new outcome measure in MS akin to disease free status, which has become a treatment goal with the expanding array of highly effective MS therapies.

Dr. Rotstein enjoys mentoring residents and grad students interested in MS clinical care and research. In addition, she is actively involved in international neurology education. In 2009, she founded the Neurology International Residents’ Videoconferencing Exchange (NIRVE) and now serves as the faculty mentor for this program. This monthly educational videoconference connects residents at sites in Toronto, France, Russia, and Brazil to learn about common neurologic diseases.

Please note: Dr. Rotstein is not taking any summer students.

Recent Publications

  1. Rotstein, DL, Yeh, EA. Could wider social networks prevent disability in MS and other neurologic disorders?. Neurology. 2020;95 (11):463-464. doi: 10.1212/WNL.0000000000010452. PubMed PMID:32769138 .
  2. Rotstein, DL, Marrie, RA, Tu, K, Schultz, SE, Fung, K, Maxwell, CJ et al.. Health service utilization in immigrants with multiple sclerosis. PLoS One. 2020;15 (7):e0234876. doi: 10.1371/journal.pone.0234876. PubMed PMID:32645017 PubMed Central PMC7347150.
  3. Rotstein, DL, Sawicka, K, Bharatha, A, Montalban, X, Lipton, JH. CNS demyelination after initiating the tyrosine kinase inhibitor imatinib: A report of two cases. Mult Scler. 2020;26 (9):1121-1124. doi: 10.1177/1352458519892914. PubMed PMID:31845621 .
  4. Rotstein, DL, Marrie, RA, Maxwell, C, Gandhi, S, Schultz, SE, Fung, K et al.. MS risk in immigrants in the McDonald era: A population-based study in Ontario, Canada. Neurology. 2019;93 (24):e2203-e2215. doi: 10.1212/WNL.0000000000008611. PubMed PMID:31690681 PubMed Central PMC6937488.
  5. Rotstein, DL. Disease-modifying therapies should be stopped in NMOSD patients in remission - No. Mult Scler. 2019;25 (9):1218-1220. doi: 10.1177/1352458519832249. PubMed PMID:30900934 .
  6. Rotstein, DL, Cortese, M, Fung, TT, Chitnis, T, Ascherio, A, Munger, KL et al.. Diet quality and risk of multiple sclerosis in two cohorts of US women. Mult Scler. 2019;25 (13):1773-1780. doi: 10.1177/1352458518807061. PubMed PMID:30351179 PubMed Central PMC6478561.
  7. Rotstein, DL, Bharatha, A, Selchen, D. Severe aseptic temporal lobe encephalitis on fingolimod. Mult Scler Relat Disord. 2018;23 :4-6. doi: 10.1016/j.msard.2018.04.008. PubMed PMID:29689473 .
  8. Rotstein, DL, Chen, H, Wilton, AS, Kwong, JC, Marrie, RA, Gozdyra, P et al.. Temporal trends in multiple sclerosis prevalence and incidence in a large population. Neurology. 2018;90 (16):e1435-e1441. doi: 10.1212/WNL.0000000000005331. PubMed PMID:29549225 .
  9. Rotstein, DL. A protean disease: The phenotypic range of neuromyelitis optica spectrum disorder. Mult Scler. 2018;24 (5):688-689. doi: 10.1177/1352458517726867. PubMed PMID:28814129 .
  10. Fischer, CE, Golas, AC, Schweizer, TA, Munoz, DG, Ismail, Z, Qian, W et al.. Anti N-methyl-D-aspartate receptor encephalitis: a game-changer?. Expert Rev Neurother. 2016;16 (7):849-59. doi: 10.1080/14737175.2016.1184088. PubMed PMID:27123777 .
Search PubMed

Affiliations & Other Activities

  • Neurologist, Multiple Sclerosis Clinic, St. Michael’s Hospital
  • Assistant Professor, Department of Medicine, Division of Neurology, University of Toronto.